The therapeutic potential of BACE1 silencing has been proposed several times due to its direct association with neurodegeneration and accumulation of APP products (Singer et al., 2005; Sun et al., 2006; Wang et al., 2018) during early stages of Alzheimer’s disease. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.